Clinical Trial Update: Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating retrograde autologous priming and mannitol to reduce hemodilution in cardiac surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Heart Disease

Drugs mentioned

• Mannitol (mannitol)
• Retrograde autologous priming

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Hemodilution, Coronary Artery Disease | Phase 3 | Status: WITHDRAWN